# Study to Evaluate GR1801's Efficacy and Safety

> **NCT05846568** · PHASE3 · COMPLETED · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 1200 (actual)

## Conditions studied

- Rabies Post-exposure Prophylaxis

## Interventions

- **BIOLOGICAL:** GR1801
- **BIOLOGICAL:** Human Rabies Immunoglobulin(HRIG)
- **BIOLOGICAL:** Rabies Vaccine

## Key facts

- **NCT ID:** NCT05846568
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-21
- **Primary completion:** 2023-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846568, "Study to Evaluate GR1801's Efficacy and Safety". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05846568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*